Abstract
A Surface Plasmon Resonance Imaging (SPRI) sensor has been developed for highly selective determination of cathepsin D (Cat D) or/and E (Cat E). The sensor contains immobilised pepstatin A, which binds aspartyl proteases from solution. Pepstatin A activated with N-Hydroxysuccinimide (NHS) and N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide (EDC) was immobilized on an amine-modified gold surface. Cysteamine was used for modification of the gold surface. Pepstatin A concentration and pH of interaction were optimised. A concentration of pepstatin equal to 0.5 μg mL-1 and a pH of 3.75 were selected as optimal.The sensor's dynamic response range is between 0.25 and 1.0 ng mL-1, and the detection limit is 0.12 ng mL-1. However, the sensor cannot distinguish between Cat D and Cat E. In order to demonstrate the sensor's potential, Cat E was determined in human red blood cells, Cat D in human saliva, as well as total concentration of Cat D and Cat E in human nasal polyps.
Keywords: Biosensor, cathepsin D, cathepsin E, pepstatin A, Surface Plasmon Resonance Imaging
Protein & Peptide Letters
Title: SPR Imaging Biosensor for Aspartyl Cathepsins: Sensor Development and Application for Biological Material
Volume: 17 Issue: 9
Author(s): Ewa Gorodkiewicz and Elzbieta Regulska
Affiliation:
Keywords: Biosensor, cathepsin D, cathepsin E, pepstatin A, Surface Plasmon Resonance Imaging
Abstract: A Surface Plasmon Resonance Imaging (SPRI) sensor has been developed for highly selective determination of cathepsin D (Cat D) or/and E (Cat E). The sensor contains immobilised pepstatin A, which binds aspartyl proteases from solution. Pepstatin A activated with N-Hydroxysuccinimide (NHS) and N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide (EDC) was immobilized on an amine-modified gold surface. Cysteamine was used for modification of the gold surface. Pepstatin A concentration and pH of interaction were optimised. A concentration of pepstatin equal to 0.5 μg mL-1 and a pH of 3.75 were selected as optimal.The sensor's dynamic response range is between 0.25 and 1.0 ng mL-1, and the detection limit is 0.12 ng mL-1. However, the sensor cannot distinguish between Cat D and Cat E. In order to demonstrate the sensor's potential, Cat E was determined in human red blood cells, Cat D in human saliva, as well as total concentration of Cat D and Cat E in human nasal polyps.
Export Options
About this article
Cite this article as:
Gorodkiewicz Ewa and Regulska Elzbieta, SPR Imaging Biosensor for Aspartyl Cathepsins: Sensor Development and Application for Biological Material, Protein & Peptide Letters 2010; 17 (9) . https://dx.doi.org/10.2174/092986610791760450
DOI https://dx.doi.org/10.2174/092986610791760450 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Editorial (Thematic Issue: From Gut Inflammation to Gastrointestinal Disorders Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities)
Current Pharmaceutical Design Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of Some Novel Thiazole-2- Carboxamide Derivatives as Antitumor Agents
Letters in Drug Design & Discovery Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design QSPR in Oral Bioavailability: Specificity or Integrality?
Mini-Reviews in Medicinal Chemistry Novel [6]-gingerol Triazole Derivatives and their Antiproliferative Potential against Tumor Cells
Current Topics in Medicinal Chemistry Recent Advances of Poly(ether-ether) and Poly(ether-ester) Block Copolymers in Biomedical Applications
Current Drug Metabolism Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design